Alan Scrivner

General Counsel at NEUBASE THERAPEUTICS, INC.

Health Technology

Profile

Alan Scrivner is currently the Vice President-Legal & Intellectual Property at NeuBase Therapeutics, Inc. He previously worked as the Director-Intellectual Property at AtheroGenics, Inc. from 2001 to 2007.
He also worked as an Associate General Counsel-Intellectual Property at Pharmacia Corp.

Alan Scrivner active positions

Companies	Position	Start
NEUBASE THERAPEUTICS, INC.	General Counsel	2021-08-31

All active positions of Alan Scrivner

Former positions of Alan Scrivner

Companies	Position	End
AtheroGenics, Inc. AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis.	Corporate Officer/Principal	2006-12-31
Pharmacia Corp. Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.	Corporate Officer/Principal	-

See the detail of Alan Scrivner's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Alan Scrivner's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.	Health Technology
AtheroGenics, Inc. AtheroGenics, Inc. Pharmaceuticals: MajorHealth Technology AtheroGenics is a pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, asthma and arthritis.	Health Technology
Pharmacia Corp. Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.	Health Technology

See company connections

Stock Market
Insiders
Alan Scrivner